FDA 483 - Genentech, Inc. - May 26, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Genentech, Inc. in South San Francisco, CA, a drug substance and drug product manufacturer, identified two significant observations. The firm's laboratory controls were found to lack scientifically sound standards, specifically regarding unvalidated hold times for endotoxin samples and infrequent incubator cleaning. Additionally, the Quality Unit failed to adhere to written procedures for the qualification of critical reagents, leading to an improper cell bank potency comparison.
ID · 3b630c1e-0dc5-44a8-a456-256f25c6a163